Table 2.
Relevant studies on survival following ablation of recurrent colorectal liver metastases after hepatectomy within 10 years.
| Author/Year | Type of Study | Number of Patients/Lesions | Approach of Ablation | Mean/Median Tumor Size (cm) | Mean/Median Tumor Number | Median Follow-Up Period in Months | Local Tumor Progression Rate (%) | Liver Limited Recurrence (%) | Repeat Local Treatment for Liver Limited Recurrence (%) | 3-y OS (%) | 5-y OS (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fan/2020 [143] | Retrospective | 144/258 | Percutaneous RFA | 2.6 | 5.1 | 28.6 | 7 | 79.2 * | n/a | n/a | 27.1 |
| Zimmermann/2020 [43] | Retrospective | 23/29 | Percutaneous RFA | n/a | n/a | 26 | n/a | 74 | n/a | 57 | 24 |
| Schullian/2020 [44] | Retrospective | 64/217 | Percutaneous RFA § | 2.7 | 2 | 21 | 11.5 | 48.4 * | 48.4 | 46.2 | 34.8 |
| Mao/2019 [144] | Retrospective | 61/114 | Percutaneous RFA # | 2.7 | 2 | 28.9 | 16.7 | 54.1 | 52 | n/a | 33 |
| Odisio/2018 [115] | Retrospective | 49/59 | Percutaneous RFA, MWA, and Cryoablation | n/a | n/a | 28 | 5.1 | n/a | n/a | 78 | n/a |
| Dupré/2017 [45] | Retrospective | 33/n/a | Open or percutaneous RFA, MWA, and IRE | 2 | 2 | 36.2 | n/a | 54.5 | 88.9 | 30.4 | n/a |
| Sofocleous/2011 [47] | Retrospective | 56/71 | Percutaneous RFA | 1.9 | 1.3 | 22 | 50.7 | n/a | 47.2 | 41 | n/a |
Abbreviations—n/a: not available; OS: overall survival, *: Intrahepatic distant metastases; §: stereotactic radiofrequency ablation. Retreat with RFA only. #: Resectable CLM.